Catalyst Event
Takeda Pharmaceutical Co Ltd (TAK) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/3/2026, 12:00:00 AM
The U.S. FDA ordered Takeda to add a boxed warning to Adzynma on June 3, 2026; a medium market impact is estimated due to potential safety concerns affecting sales. expected
Korean Translation
미국 FDA가 2026년 6월 3일 애드진마에 박스형 경고문 추가를 명령함. 안전성 우려에 따른 매출 영향으로 중간 수준의 시장 영향이 예상됨.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM